Citations

Clear

16280 citation(s) found for "Ha, David R".

From Priority Questions to Registry-Nested Trials: An AJRR-C Road Map for Advancing Arthroplasty Research
Hannon, Charles P , Springer, Bryan D. , Huddleston, James I , Kremers, Hilal Maradit , Lewallen, David G , Berry, Daniel J

Mayo Clinic

Journal of Bone and Joint Surgery | November 18, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.2106/jbjs.26.01407 | PMID 43050508 Get It

Background: The American Joint Replacement Research-Collaborative (AJRR-C) is a National Institutes of Health-funded P30 Core Center for Clinical Research and seeks to accelerate practice-changing arthroplasty research by leveraging the American Joint Replacement Registry (AJRR) and shared multicenter research infrastructure. The AJRR-C convened 2 complementary meetings to establish a scalable coordinated pathway from the identification of high-priority clinical questions to the initiation of prospective studies. Methods: In July 2025, leaders from The Hip Society, The Knee Society, the American Association of Hip and Knee Surgeons, the AJRR, the Orthopaedic Research and Education Foundation, and the broader research community identified and prioritized clinical research questions regarding infection, perioperative management, new technologies, surgical techniques, implants, and quality. In April 2026, orthopaedic surgeons, methodologists, and artificial intelligence experts reconvened to evaluate contemporary approaches for addressing these priorities. Results: A central theme of the meetings was the importance of utilizing a fit-for-purpose approach in which study design is tailored to the clinical question, available data, and potential sources of bias. Clinical questions with clear equipoise and feasible interventions may warrant randomization, whereas questions involving rare outcomes, rapidly evolving technologies, surgeon preferences, or long-term surveillance may be better addressed with observational studies. Participants emphasized the need for a robust, sustainable network for arthroplasty clinical trials that provides the shared infrastructure necessary for coordinated site engagement, standardized data definitions, reliable longitudinal follow-up, and AJRR linkage across multicenter trials. Two new AJRR-nested randomized trials arose from the priority-topics meeting, and their development demonstrates the potential of the AJRR-C consensus model to translate research priorities into practice-changing evidence generation. Conclusions: The AJRR-C established a coordinated pathway from the prioritization of research to the implementation of multicenter studies to address high-priority arthroplasty research questions. Sustaining this model requires continued collaboration among orthopaedic societies, investigators, methodologists, and the AJRR, as well as reliable funding mechanisms.
Longitudinal Detection of Circulating Tumor DNA in Children with Pleuropulmonary Blastoma: A Report from the International PPB/DICER1 Registry
Schultz, Kris Ann P , Field, Amanda L , Mallinger, Paige H R , Xu, Chenyu , Deonovic, Benjamin , Nelson, Alexander T , Watson, Dave , Hagedorn, Kelly , Olson, Damon R , Kamihara, Junne , Chen, Kenneth S , Mitchell, Sarah G , Wilson, David B , Amend, Christina E , Mize, William , Su, Yan , Duan, Chao , Yue, Zhixia , Gao, Chao , Klega, Kelly S. , Dehner, Louis P , Messinger, Yoav H , Crompton, Brian D , Harris, Anne K , Hill, Dana Ashley

Mayo Clinic

Clinical Cancer Research | November 17, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1158/1078-0432.ccr-26-1981 | PMID 43043066 Get It

Abstract Purpose: Pleuropulmonary blastoma (PPB) is the most common lung cancer of early childhood. Nearly all PPBs have biallelic DICER1 variants: a loss-of-function allele (often germline) and a second RNase IIIb domain "hotspot" substitution. Except in somatic mosaicism, these hotspots are tumor-specific and ideal liquid biopsy targets. Experimental Design: For individuals with PPB enrolled in the International PPB/DICER1 Registry, blood samples were collected at timepoints coordinated with clinical venous access. Tumor sequencing identified each patient's RNase IIIb hotspot, enabling personalized droplet digital PCR assays to detect that variant in circulating tumor DNA (ctDNA). Results: We analyzed 482 samples from 20 type I and 53 type II/III PPB patients. Among 13 pre-operative type II/III patients sampled pretreatment, 11 (85%) had detectable ctDNA, with tumor size moderately correlated with ctDNA burden (Spearman's ρ=0.574, p=0.051). In contrast, among 8 patients sampled after resection but before chemotherapy, none had detectable ctDNA (p<0.001 vs. unresected). After chemotherapy initiation, ctDNA levels spiked within 1–2 days before rapidly declining. During post-event surveillance, ctDNA was detectable a median of 5.3 weeks before clinical progression (21.7 weeks for negative samples; p=0.001). In type I PPB, DICER1 variants were detectable only in patients with somatic mosaicism. Conclusions: In type II/III PPB, ctDNA correlates with tumor size and resection status. The transient rise and fall in ctDNA following initiation of chemotherapy suggests that ctDNA could serve as a real-time in vivo assay of tumor responsiveness, and these findings support further investigation as a pharmacodynamic biomarker for disease response and recurrence detection.
Thermal Safety of Temperature Mapping During Trigeminal Radiofrequency Rhizotomy
Staudt, Michael D. , Grewal, Sanjeet S. , Yang, Flora J., Holland, Marshall T. , Darrow, David

Mayo Clinic

Operative Neurosurgery | November 16, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1227/ons.0000000000002243 | PMID 43037603 Get It

BACKGROUND AND OBJECTIVES: Radiofrequency (RF) rhizotomy of the Gasserian ganglion is an established treatment for trigeminal neuralgia that requires accurate localization before lesioning. Temperature-based interrogation has been proposed as a localization strategy, but its thermal safety margin has not been quantified. We quantified thermal injury risk of temperature mapping relative to definitive lesioning. METHODS: Thermocouple logs from 12 patients undergoing RF rhizotomy with a cylindrical platinum band electrode (0.8-mm diameter, 2.0-mm contact length) included 54 mapping and 19 definitive lesion episodes. Arrhenius injury dose was computed from temperature–time data. A reduced-order effective-medium model of the Gasserian ganglion, parameterized by cerebrospinal fluid fraction and distributed heat exchange, was calibrated to burn episodes and applied to mapping episodes. Sensitivity analyses evaluated 2 Arrhenius parameter sets and ±2°C thermocouple bias. RESULTS: The Arrhenius damage integral (Ω; Ω ≥ 1 indicating predicted irreversible injury) at the thermocouple was far lower during mapping than during definitive lesioning. Under neural-relevant parameters, median mapping Ω was 3.73 × 10 −4 (IQR 4.16 × 10 −5 -1.65 × 10 −3 ; maximum 9.92 × 10 −3 ) vs 1.85 × 10 3 (IQR 5.90 × 10 1 -3.36 × 10 3 ) during burns. Predicted burn lesion radii were 1.8 to 2.2 mm, while mapping radius was 0 mm across all episodes. Mapping remained subthreshold under canonical RF parameters and ±2°C bias. CONCLUSION: Temperature mapping using multicontact cylindrical electrodes produced exposures several orders of magnitude below lesioning thresholds. These findings support a substantial thermal safety margin for temperature mapping during trigeminal RF rhizotomy.
Can Pediatric Emergency Medicine Clinicians Identify Solid Organ Injuries Using Contrast‐Enhanced FAST in Abdominal Trauma?
Leff, Rebecca , Kummer, Tobias , Nagler, Joshua , Lev, Hannah J , Mooney, David , Molinari, Daniel Fiterman , Gravel, Cynthia A

Mayo Clinic

Journal of Clinical Ultrasound | November 16, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1002/jcu.70471 | PMID 43035326 Get It

ABSTRACT Background Contrast‐enhanced FAST (cFAST) has demonstrated superior sensitivity to B‐mode FAST for detecting solid organ injury in blunt abdominal trauma, yet no prior study has evaluated cFAST image interpretation by pediatric emergency medicine (PEM) clinicians. We evaluated the sensitivity and specificity of cFAST interpretation for solid organ injuries by PEM clinicians following a web‐based didactic. Methods In this prospective, single‐center study (February–May 2026), PEM clinicians credentialed in B‐mode FAST without prior cFAST training completed a web‐based didactic. Participants interpreted 12 simulated cases (25 cine clips), evaluating 41 organs (15 injured, 26 non‐injured), all reviewed by a cFAST expert or cFAST‐trained pediatric radiologist with CT confirmation. Pooled organ‐level sensitivity and specificity were calculated with clustering correction using robust standard errors. Results Among 41 participants, 1681 organ‐level decisions were analyzed. Pooled sensitivity was 87.97% (95% CI: 84.96%–91.09%), specificity was 89.12% (95% CI: 86.53%–91.78%), negative predictive value (NPV) was 92.77% (95% CI: 90.99%–94.59%), and positive predictive value was 82.34% (95% CI: 78.68%–86.17%). False‐negative decisions occurred in 4.4% ( n = 74/1681). Conclusion After a web‐based curriculum, PEM clinicians achieved high sensitivity, specificity, and NPV with few missed injuries, supporting future investigation of cFAST as an adjunctive screening tool in pediatric blunt abdominal trauma risk‐stratification assessments.
Artificial Intelligence Models to Predict Recurrence in Patients with Differentiated Thyroid Cancer: A PROBAST + AI Systematic Review of Clinical Applicability
Solis-Pazmino, Paola , Samaniego, Alison Fernanda , Laurini de Souza Meyer, Erika , Pilatuna, Eduardo A , González-Velázquez, Camilo , Lincango, Eddy P., Figueroa, Luis A , Toro-Tobon, David

Mayo Clinic

Thyroid® | November 12, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1177/10507256261504546 | PMID 43018984 Get It

Background: Differentiated thyroid cancer (DTC) generally carries an excellent prognosis, yet recurrence occurs in up to 8–9% of patients. Artificial intelligence (AI) models are increasingly proposed to predict DTC recurrence; however, their methodological quality and clinical readiness are poorly defined. We conducted a systematic review to evaluate the methodological quality, risk of bias, and applicability of these models using the PROBAST + AI framework. Methods: We searched Ovid MEDLINE, Embase, Cochrane databases, Scopus, and Web of Science from inception to July 13, 2026. Eligible studies included original research developing or validating AI models for recurrence in DTC. Model quality (for development), risk of bias (for evaluation), and applicability were assessed using the PROBAST + AI framework, with a focus on discrimination, calibration, and validation strategies (PROSPERO; registration number [CRD420251004644]). Results: Of 673 records screened, 34 studies were included (21 unique datasets and 13 UCI-derived publications), encompassing 21,267 patients with a recurrence rate of 7.8%. Most were developed in Asian cohorts (17 of 21 datasets) and were structured clinical/tabular variables (82.4%), including demographic, clinical, laboratory, and pathological data, whereas the remaining models incorporated multimodal inputs such as imaging-derived or radiomic features. Notably, nearly one quarter of included studies (13 of 34, 38%) represented reanalysis of a single dataset. Discrimination was reported in 22 of 34 studies (64.7%) (area under the receiver operating characteristic curve [AUC] 0.67–1.00), though only 10 studies assessed calibration, none with standardized metrics. The PROBAST + AI assessment revealed high overall quality concerns in 26 of 34 (76.5%) development studies due to reliance on single-center cohorts, inadequate handling of missing data, and absence of external validation. Only 6 of 34 included studies (17.6%) were judged to have low overall quality concern, whereas 17 of 34 (50.0%) were rated as having low applicability concern. Conclusions: AI models for predicting DTC recurrence show promising discriminatory performance but have substantial methodological shortcomings in development, and a lack of calibration and external validation necessary for clinical use. Given the guidelines’ emphasis on risk-adapted de-escalation of therapy, the development of robust, validated, and clinically calibrated AI tools is a priority. Current evidence remains insufficient to support routine clinical use.
Long-term economic benefits of early cancer detection through enhanced multimodal screening: a modeling study of whole-body MRI and liquid biopsy
Sato, Ryoko , McVeigh, Kim H, Bolan, Candice, Brar, Pamila, Sazama, Naomi, Karow, David

Mayo Clinic

Journal of Comparative Effectiveness Research | November 11, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.57264/cer-2026-0099 | PMID 43012102 Get It

Aim: Cancer poses a substantial health and economic burden in the US Although early detection is associated with improved outcomes and lower treatment costs, many cancers are still diagnosed at advanced stages. Enhanced multimodal screening combining whole-body magnetic resonance imaging (WB MRI) and blood-based multicancer early detection (MCED) may shift diagnoses earlier, but its long-term economic impact remains uncertain. Materials & methods: We developed an economic model to estimate expected cancer-related costs under two scenarios: status quo with conventional screening and enhanced multimodal screening incorporating WB MRI and MCED. The analysis included common cancers with an annual incidence of ≥10,000 new cases in the US in 2025. Expected cancer management costs were estimated using incidence-based 5-year stage-specific medical costs. Productivity losses were estimated using a simplified human capital approach, applying published stage-specific work-loss durations to sex-specific annual earnings. Under the intervention arm, conservative, moderate and maximum cancer stage-shift assumptions were evaluated. These scenarios reflected increasing degrees of earlier cancer detection, with a greater proportion of cancers assumed to be diagnosed at earlier stages rather than at advanced stages. Total expected cancer-related costs per person were derived by combining direct medical costs and productivity losses, weighted by cancer risk and stage distribution. Results: Under the status quo, expected cancer-related costs were estimated at $74,431 for men and $78,818 for women. With enhanced multimodal screening under the moderate stage-shift assumption, costs, including screening and false positive workup, declined to about $66,000 and $69,500, respectively, representing approximately 12% reduction. Under the conservative stage-shift assumption, total costs were similar to those under the status quo, whereas under the maximum stage-shift assumption, cost reductions ranged from 24.0% to 24.3% for men and from 24.7% to 25.0% for women. Conclusion: Enhanced multimodal screening may reduce the economic burden of cancer by shifting diagnosis toward earlier stages, although the magnitude of benefit depends substantially on the extent to which cancers are detected at earlier stages in practice. These findings highlight the potential long-term economic value of earlier cancer detection while underscoring the need for prospective evidence on the real-world performance of WB-MRI and MCED screening strategies. Because long-term real-world data for population-level WB-MRI and MCED screening remain limited, these findings should be interpreted as estimates of potential economic impact rather than projections of a specific screening program.
What’s New in Adult Reconstructive Knee Surgery
Luo, T David , Lum, Zachary C , Rosas, Samuel , Deckey, David G , Lanting, Brent A.

Mayo Clinic

Journal of Bone and Joint Surgery | November 10, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.2106/jbjs.26.01250 | PMID 43008105 Get It

Evaluating Age-Related Motor System Changes Using Gait as a Functionally Relevant Marker
You, Victor S , Barnard, Leland , Botha, Hugo , Graff-Radford, Jonathan , Vemuri, Prashanthi , Jack, Clifford R , Knopman, David S. , Windham, Beverly Gwen , Petersen, Ronald C , Ali, Farwa

Mayo Clinic

Neurology | November 10, 2026 | Volume: 107 | Issue: 11 | Pages: No page available

10.1212/wnl.0000000000218766 | PMID 43008257 Get It

Non–Prostate Cancer‐Related Factors That Influence Serum Prostate‐Specific Antigen: A Narrative Review of 45 Non‐Malignant PSA Modifiers
Stephan, Carsten , Jung, Klaus , Sutcliffe, Siobhan , Filella, Xavier , Phillips, Michael B. , Wolinsky, Howard , Ginsburg, Kevin , Keller, David K.

Mayo Clinic

The Prostate | November 9, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1002/pros.70272 | PMID 43002634 Get It

ABSTRACT Background To consolidate into a single review more than forty non‐cancer‐related factors that have been found to elevate or reduce prostate‐specific antigen (PSA) levels in the peer‐reviewed literature, emphasizing their contribution to false‐positive and false‐negative clinical interpretations. Materials and Methods A narrative literature review was conducted using PubMed, focusing on human studies describing benign physiologic, infectious, inflammatory, iatrogenic, hormonal, pharmacologic, and laboratory‐related factors that influence PSA values. The review emphasizes contemporary studies but incorporates earlier foundational literature where relevant. Results Forty‐five non‐cancer‐related factors were identified that influence PSA values through biologic, mechanical, pharmacologic, or analytic mechanisms. Thirty factors were associated with transient or persistent PSA elevation, whereas fifteen were associated with PSA reduction. Some factors varied substantially in the strength, magnitude, and consistency of reported PSA effects across studies. PSA elevations were reported in association with prostatic inflammation or infection, urinary retention, ejaculation, non‐instrumental prostatic physical stimulation, urologic instrumentation, and systemic inflammatory conditions. PSA reductions were observed with medications including 5‐alpha‐reductase inhibitors, nonsteroidal anti‐inflammatory drugs, statins, thiazide diuretics, metformin, and certain lifestyle factors. Inter‐assay and inter‐laboratory variability alone has been reported to result in PSA differences exceeding 20%. Tables summarizing the approximate magnitude and duration of PSA change for each modifier were developed, along with a patient questionnaire intended to support, not replace, clinician judgment. Conclusion PSA interpretation must incorporate awareness of more than forty influencers that can alter PSA independent of any malignancy. Accounting for these PSA level‐altering variables can improve PSA test result specificity and enhance confidence in prostate cancer risk assessment. Use of a structured patient questionnaire, a thorough consideration of benign factors that can alter PSA, repeat testing when transient factors are present, and consistent blood assay methodology can reduce unnecessary imaging, unneeded biopsies, and missed malignancies.
Targeting NF-κB prevents Schwann cell reprogramming and plexiform neurofibroma initiation in mouse model of Nf1
Ravindran, Ramya , Youn, Eui-Kyung, Kedei, Noémi , Choi, Kwangmin , Volz, Avery, Dombi, Eva , Pundavela, Jay , Kim, MiOk, Spinner, Robert J. , Szabo, Sara , Largaespada, David A. , Shern, Jack F. , Ratner, Nancy

Mayo Clinic

No container title available | November 6, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.64898/2026.11.04.764357 Get It

Plexiform neurofibromas arise in approximately half of all individuals with Neurofibromatosis Type I (NF1). Genetic lesions apart from NF1 pathogenic variants are not present in NF1 mutant Schwann cells, suggesting that tumorigenesis may instead require cellular rewiring. To identify putatively re-wired tumor cells, we used multiplex imaging and flow cytometry to delineate markers that distinguish tumor Schwann cell from non-tumor Schwann cells. We identified tumor Schwann cells as CD44+;CD49f+ cells that show increased transcription of epithelial to mesenchymal plasticity (EMP)- associated genes. CD44+;CD49f+ expression was induced by treating Nf1-/- Schwann cells with stressors or by direct NF-κB pathway activation via IKK2; treated Schwann cells increased secretion of NF-κB targets and immune cell chemoattractants CCL2 and CCL3. In established tumors, MEK inhibition plus NF-κB blockade diminished tumor cell proliferation, tumor Schwann cells, immune cell populations, tumor cytokines and tumor number. Notably, transient single agent NF-κB pathway blockade was sufficient to significantly delay tumor formation in mice. Thus, Nf1 loss in Schwann cells is followed by NF-κB activation and cellular reprogramming that drives tumor initiation and targeting NF-κB activation can reduce NF1-deficient tumor formation.